Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind crossover FRI study of BGF versus GFF in COPD
2018-001704-10Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of budesonide, glycopyrronium and formoterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by AstraZeneca. Primary endpoints: Change from baseline in specific airway volume and Change from baseline in specific airway resistance. Started Aug 2018; status: completed.
02
Drugs
budesonideglycopyrroniumformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2018-001704-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001704-10.